Related Experiment Video
Updated: Oct 9, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.5K
Cancer Therapy Targeting CD47/SIRPα
Nazli Dizman1, Elizabeth I Buchbinder2
1Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA.
Cancers
|December 24, 2021
Summary
Targeting the CD47-SIRPα pathway shows promise in cancer immunotherapy. Agents blocking this interaction are demonstrating safety and preliminary efficacy in early clinical trials for various cancers.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Cancer immunotherapy has seen significant advancements, particularly with immune checkpoint blockers.
- CD47 is a molecule overexpressed in many cancers, aiding immune evasion.
- SIRPα is the ligand for CD47, forming a critical axis for immune regulation.
Purpose of the Study:
- To provide an overview of the mechanistic rationale for targeting the CD47-SIRPα axis.
- To summarize the preclinical and clinical evidence for CD47/SIRPα-directed agents.
Main Methods:
- Review of preclinical studies investigating CD47/SIRPα targeting agents.
- Analysis of early-phase clinical trial data for agents directed to the CD47/SIRPα axis.
Main Results:
- CD47/SIRPα-directed agents have shown preclinical activity against various cancer types.
- Early clinical trials indicate that CD47/SIRPα agents are safe with preliminary signs of efficacy.
Conclusions:
- The CD47-SIRPα axis is a promising therapeutic target in cancer immunotherapy.
- Further clinical investigation of CD47/SIRPα-directed agents is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:27Tumor Immunotherapy
721
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
721
02:50Combination Therapies and Personalized Medicine
5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:38Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K